US CRO contracted by FDA to answer generics safety questions

- Last updated on GMT

US CRO contracted by FDA to answer generics safety questions
CRO Vince & Associated Clinical Research (VACR) has won a $5m grant to conduct bioequivalence studies for the US FDA.

Under the contract, Kansas-based VACR will compare generic drugs with innovator products with the initial focus being on anti-epileptic products.

The contract research organisations (CRO)'s president Brad Vince said that: “With this contract we will seek to investigate the bioequivalence of generic products that have resulted in reports of Adverse Events to the FDA​.”

He added that: “We are truly excited to partner with the FDA to help address agency concerns with product substitution issues​.”

Related topics: Clinical Development, Phase III-IV

Related news

Show more

Related products


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers